She has 25-year experience, and is a leading expert in the field of purinergic signalling in the nervous system publishing over 65 full papers on this broad field.

Her major achievements are the discovery of the presynaptic P2X7 purinergic receptors regulating neurotransmission, identification of novel ATP release and glia-neuron cross-talk mechanisms and validation of P2X7 receptor as a new drug target in psychiatric and mood disorders. She is the Co-PI of an ERC Advanced Investigator grant and is also involved in in preclinical drug-development, owning patents and contracting with pharma industry. She currently has a 12-member research team applying multidisciplinary biomedical technology (molecular biology, in vivo imaging, electrophysiology, pharmacology, neurochemistry, behavior studies) to identify new purinergic drug targets in CNS disorders. Dr. Sperlágh is the President of the Hungarian Society for Experimental and Clinical Pharmacology; the Associate Editor of Purinergic Signalling, the Section Editor of Brain Research Bulletin, Inflammopharmacology, the Editorial Board member of British Journal of Pharmacology, Neurochemistry International and Neurochemical Research.